Compare XNCR & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNCR | INSP |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2013 | 2018 |
| Metric | XNCR | INSP |
|---|---|---|
| Price | $23.51 | $74.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 16 |
| Target Price | $22.33 | ★ $94.00 |
| AVG Volume (30 Days) | ★ 1.3M | 506.8K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 65.36 | ★ 179.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | $4.80 | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.65 | ★ 62.18 |
| 52 Week Low | $8.49 | $38.91 |
| 52 Week High | $30.61 | $147.03 |
| Indicator | XNCR | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 77.88 |
| Support Level | $11.20 | $53.39 |
| Resistance Level | $30.61 | $86.00 |
| Average True Range (ATR) | 1.45 | 3.04 |
| MACD | -0.70 | 0.93 |
| Stochastic Oscillator | 9.93 | 93.66 |
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.